Manejo actual del glioblastoma multiforme

Autores:: Moscote Salazar, Luís Rafael
Meneses García, Carlos
Sáenz Amuruz, Miguel
Penagos, Pedro
Zubieta, Camilo
Romero, Alfredo

Tipo de recurso:: Article of journal

Fecha de publicación:: 2020

Institución:: Universidad de Cartagena

Repositorio:: Repositorio Universidad de Cartagena

Idioma:: spa

id	UCART2_27023a2f3c46ab19abf9c0152230d317
oai_identifier_str	oai:repositorio.unicartagena.edu.co:11227/13361
network_acronym_str	UCART2
network_name_str	Repositorio Universidad de Cartagena
repository_id_str
dc.title.spa.fl_str_mv	Manejo actual del glioblastoma multiforme
dc.title.translated.eng.fl_str_mv	Manejo actual del glioblastoma multiforme
title	Manejo actual del glioblastoma multiforme
spellingShingle	Manejo actual del glioblastoma multiforme Glioblastoma. Tumores cerebrales. Gliomas malignos.
title_short	Manejo actual del glioblastoma multiforme
title_full	Manejo actual del glioblastoma multiforme
title_fullStr	Manejo actual del glioblastoma multiforme
title_full_unstemmed	Manejo actual del glioblastoma multiforme
title_sort	Manejo actual del glioblastoma multiforme
dc.creator.fl_str_mv	Moscote Salazar, Luís Rafael Meneses García, Carlos Sáenz Amuruz, Miguel Penagos, Pedro Zubieta, Camilo Romero, Alfredo
dc.contributor.author.spa.fl_str_mv	Moscote Salazar, Luís Rafael Meneses García, Carlos Sáenz Amuruz, Miguel Penagos, Pedro Zubieta, Camilo Romero, Alfredo
dc.subject.spa.fl_str_mv	Glioblastoma. Tumores cerebrales. Gliomas malignos.
topic	Glioblastoma. Tumores cerebrales. Gliomas malignos.
publishDate	2020
dc.date.accessioned.none.fl_str_mv	2020-12-22 00:00:00
dc.date.available.none.fl_str_mv	2020-12-22 00:00:00
dc.date.issued.none.fl_str_mv	2020-12-22
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.eng.fl_str_mv	Journal article
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	2215-7840
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/11227/13361
dc.identifier.doi.none.fl_str_mv	10.32997/rcb-2010-3093
dc.identifier.eissn.none.fl_str_mv	2389-7252
dc.identifier.url.none.fl_str_mv	https://doi.org/10.32997/rcb-2010-3093
identifier_str_mv	2215-7840 10.32997/rcb-2010-3093 2389-7252
url	https://hdl.handle.net/11227/13361 https://doi.org/10.32997/rcb-2010-3093
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Ciencias Biomédicas
dc.relation.bitstream.none.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3093/2621
dc.relation.citationedition.spa.fl_str_mv	Núm. 2 , Año 2010
dc.relation.citationendpage.none.fl_str_mv	245
dc.relation.citationissue.spa.fl_str_mv	2
dc.relation.citationstartpage.none.fl_str_mv	237
dc.relation.citationvolume.spa.fl_str_mv	1
dc.relation.references.spa.fl_str_mv	Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival, J Neurosurg, 2001;95:190–98. Stewart LA, Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials, Lancet, 2002;359:1011–18 O’Reilly SM, Newlands ES, Glaser MG, et al., Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours, Eur J Cancer, 1993;29A:940–42 Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide, J Clin Oncol, 2002;20:1375–82. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T; ALA-Glioma Study Group.Neurosurgery. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.2008 Mar;62(3):564-76; discussion 564-76 Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Pinto LW, Araújo MB, Vettore AL, Wernersbach L, Leite AC, Chimelli LM, Soares FA. Virchows Arch. 2008 May;452(5):481-90. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 2005;352:987–96. Westphal M, Hilt DC, Bortey E, et al., A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, Neuro Oncol, 2003;5:79–88. Vredenburgh JJ, Desjardins A, Herndon JE II, et al., Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin Cancer Res, 2007;13:1253–9. Maxwell JA, Johnson SP, Quinn JA, et al., Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma, Mol Cancer Ther, 2006;5:2531–9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333-43. Brada M, Thomas DG, Bleehan NM, Roberts JT, Senanayake F, Abram P, et al. Medical Research Council (MRC) randomized trial of adjuvant chemotherapy on high grade glioma (HGG)-BR05. Proc Am Soc Clin Oncol. 1998;17: A1543. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, et al. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990;18:321-4. Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino- 12,13- dihydro-13-(beta-D-glucopyranosyl) -5H-indolo [2,3-a]-pyrrolo[3,4-c]- carbazole-5,7(6H)- dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 2001;48:250-4. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997- 1003. Pech IV, Peterson K, Cairncross JG. Chemotherapy for brain tumors. Oncology. 1998;12:537- 43. Williston Park.Russell D, Rubinstein L. Pathology of Tumors of the Central Nervous System. 5th ed. Baltimore, Williams & Wilkins, 1989, p. 1012. Helseth A, Mark SJ. Neoplasms of the central nervous system in Norway: III. Epidemiological characteristics of intracranial gliomas according to histology. A.P.M.I.S. 1989; 97: 547–55. Wong ML, Prawira A, Kaye AH, Hovens CM. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci. 2009 Sep;16(9):1119-30. Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg. 2003; 98(6): 1175-81. Beany RP. Positron emission tomography in the study of hu-man tumors. Sem Nucl Med 1984;14:324-41. Silverman DHS, Hoh CK, Seltzer MA, Schiepers C, Cuan GS Gambir SS, et al. Evaluating Tumor Biology and Oncological Disease with Positron Emission Tomography. Seminars in Ra- diation Oncology 1998;3:183-96. Hawkins RA, Hoh C, Dahlbom M, Choi Y, Glaspy J, Tse N, et al. PET cancer evaluations with FDG. J Nucl Med 1991;32(8): 1555-8. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncologic applications of positron emission tomo-graphy with fl uorine-18 fl uorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74. Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med 1996;37(7):1180-2. Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, et al. Detection of Malignant Tumors: whole-body PET with fl uorine 18 alpha-methyl tyrosine versus FDG-preliminary study. Radiology 2001;220:54-62. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feld- mann HJ, et al. O-(2-[18F] fl uoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27(5):542-9 Cairncross JG, Ueki K, Zlatescu MC, et al. Specifi c genetic predictors of chemo therapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473–1479 Madajewicz S, Chowhan N, Tfayli A, Roque C,et al. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy. Cancer. 2000 May 15;88(10):2350-6 Robins HI, Lassman AB, Khuntia D.Therapeutic advances in malignant glioma: current status and future prospects. Neuroimaging Clin N Am. 2009 Nov;19(4):647-56. Brandes AA, Franceschi E, Tosoni A, et al: MGMT promoter methylation status can predict incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma. J Clin Oncol 26:2192- 2197, 2008 Taal W, Brandsma D, de Bruin HG, et al: Incidence of pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405- 4 1 0 , 2008 Hoffman WF, Levin VA, Wilson CB. Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg 50:624-628, 1979 Scott JN, Rewcastle NB, Brasher PM, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999 Aug;46(2):183–8. Korshunov A, Sycheva R, Golanov A. The prognostic relevance of mo lecular alterations in glioblastomas for patients age < 50 years. Cancer 2005 Aug 15;104(4):825–32.
dc.rights.spa.fl_str_mv	Revista Ciencias Biomédicas - 2020
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Revista Ciencias Biomédicas - 2020 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Universidad de Cartagena
dc.source.spa.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3093
institution	Universidad de Cartagena
bitstream.url.fl_str_mv	https://repositorio.unicartagena.edu.co/bitstreams/27625ed8-a858-4330-8a3f-3c63a6130d35/download
bitstream.checksum.fl_str_mv	1dbbb0d3b9e9162b0624376cf083b05d
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1814214135726997504
spelling	Moscote Salazar, Luís RafaelMeneses García, CarlosSáenz Amuruz, MiguelPenagos, PedroZubieta, CamiloRomero, Alfredo2020-12-22 00:00:002020-12-22 00:00:002020-12-222215-7840https://hdl.handle.net/11227/1336110.32997/rcb-2010-30932389-7252https://doi.org/10.32997/rcb-2010-3093application/pdfspaUniversidad de CartagenaRevista Ciencias Biomédicashttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3093/2621Núm. 2 , Año 201024522371Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival, J Neurosurg, 2001;95:190–98.Stewart LA, Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials, Lancet, 2002;359:1011–18O’Reilly SM, Newlands ES, Glaser MG, et al., Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours, Eur J Cancer, 1993;29A:940–42Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide, J Clin Oncol, 2002;20:1375–82.Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T; ALA-Glioma Study Group.Neurosurgery. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.2008 Mar;62(3):564-76; discussion 564-76Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Pinto LW, Araújo MB, Vettore AL, Wernersbach L, Leite AC, Chimelli LM, Soares FA. Virchows Arch. 2008 May;452(5):481-90.Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 2005;352:987–96.Westphal M, Hilt DC, Bortey E, et al., A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, Neuro Oncol, 2003;5:79–88.Vredenburgh JJ, Desjardins A, Herndon JE II, et al., Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin Cancer Res, 2007;13:1253–9.Maxwell JA, Johnson SP, Quinn JA, et al., Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma, Mol Cancer Ther, 2006;5:2531–9.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333-43.Brada M, Thomas DG, Bleehan NM, Roberts JT, Senanayake F, Abram P, et al. Medical Research Council (MRC) randomized trial of adjuvant chemotherapy on high grade glioma (HGG)-BR05. Proc Am Soc Clin Oncol. 1998;17: A1543.Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, et al. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990;18:321-4.Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino- 12,13- dihydro-13-(beta-D-glucopyranosyl) -5H-indolo [2,3-a]-pyrrolo[3,4-c]- carbazole-5,7(6H)- dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 2001;48:250-4.Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997- 1003.Pech IV, Peterson K, Cairncross JG. Chemotherapy for brain tumors. Oncology. 1998;12:537- 43.Williston Park.Russell D, Rubinstein L. Pathology of Tumors of the Central Nervous System. 5th ed. Baltimore, Williams & Wilkins, 1989, p. 1012.Helseth A, Mark SJ. Neoplasms of the central nervous system in Norway: III. Epidemiological characteristics of intracranial gliomas according to histology. A.P.M.I.S. 1989; 97: 547–55.Wong ML, Prawira A, Kaye AH, Hovens CM. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci. 2009 Sep;16(9):1119-30.Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg. 2003; 98(6): 1175-81.Beany RP. Positron emission tomography in the study of hu-man tumors. Sem Nucl Med 1984;14:324-41.Silverman DHS, Hoh CK, Seltzer MA, Schiepers C, Cuan GS Gambir SS, et al. Evaluating Tumor Biology and Oncological Disease with Positron Emission Tomography. Seminars in Ra- diation Oncology 1998;3:183-96.Hawkins RA, Hoh C, Dahlbom M, Choi Y, Glaspy J, Tse N, et al. PET cancer evaluations with FDG. J Nucl Med 1991;32(8): 1555-8.Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncologic applications of positron emission tomo-graphy with fl uorine-18 fl uorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74.Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med 1996;37(7):1180-2.Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, et al. Detection of Malignant Tumors: whole-body PET with fl uorine 18 alpha-methyl tyrosine versus FDG-preliminary study. Radiology 2001;220:54-62.Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feld- mann HJ, et al. O-(2-[18F] fl uoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27(5):542-9Cairncross JG, Ueki K, Zlatescu MC, et al. Specifi c genetic predictors of chemo therapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473–1479Madajewicz S, Chowhan N, Tfayli A, Roque C,et al. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy. Cancer. 2000 May 15;88(10):2350-6Robins HI, Lassman AB, Khuntia D.Therapeutic advances in malignant glioma: current status and future prospects. Neuroimaging Clin N Am. 2009 Nov;19(4):647-56.Brandes AA, Franceschi E, Tosoni A, et al: MGMT promoter methylation status can predict incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma. J Clin Oncol 26:2192- 2197, 2008Taal W, Brandsma D, de Bruin HG, et al: Incidence of pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405- 4 1 0 , 2008Hoffman WF, Levin VA, Wilson CB. Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg 50:624-628, 1979Scott JN, Rewcastle NB, Brasher PM, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999 Aug;46(2):183–8.Korshunov A, Sycheva R, Golanov A. The prognostic relevance of mo lecular alterations in glioblastomas for patients age < 50 years. Cancer 2005 Aug 15;104(4):825–32.Revista Ciencias Biomédicas - 2020https://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccesshttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3093Glioblastoma. Tumores cerebrales. Gliomas malignos.Manejo actual del glioblastoma multiformeManejo actual del glioblastoma multiformeArtículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articleJournal articlePublicationOREORE.xmltext/xml2456https://repositorio.unicartagena.edu.co/bitstreams/27625ed8-a858-4330-8a3f-3c63a6130d35/download1dbbb0d3b9e9162b0624376cf083b05dMD5111227/13361oai:repositorio.unicartagena.edu.co:11227/133612024-09-05 15:30:37.044https://creativecommons.org/licenses/by-nc-sa/4.0/Revista Ciencias Biomédicas - 2020metadata.onlyhttps://repositorio.unicartagena.edu.coBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.com

Manejo actual del glioblastoma multiforme

Publicaciones similares